Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million upfront fee.The two companies will apply Monte Rosa’s QuEEN platform to develop molecular glue therapies against targets in cancer and neurological diseases that were “previously […]
